Advertisement

Topics

AACR 2018: Neoadjuvant nivolumab was safe, yielded pathologic responses in patients with resectable lung cancer

11:04 EDT 16 Apr 2018 | ecancermedicalscience

The anti-PD1 immunotherapy nivolumab given prior to surgical resection of stage 1-3 non-small cell lung cancer (NSCLC) was safe and resulted in major pathological responses in 45 percent of the patients, according to data from a clinical trial presented...

Original Article: AACR 2018: Neoadjuvant nivolumab was safe, yielded pathologic responses in patients with resectable lung cancer

NEXT ARTICLE

More From BioPortfolio on "AACR 2018: Neoadjuvant nivolumab was safe, yielded pathologic responses in patients with resectable lung cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...